Sen-Jam Pharmaceutical's Innovation in Addiction Treatment
Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company, has recently achieved a significant milestone in the fight against addiction with the announcement of a new U.S. provisional patent. This patent, titled "Compositions and Methods for Stimulant Withdrawal", represents an important advancement in the company's commitment to developing non-opioid therapeutic solutions for addiction treatment.
The Growing Stimulant Crisis
Currently, more than 1.6 million individuals in the U.S. are affected by methamphetamine use disorder. Alarmingly, deaths related to stimulant overdoses have risen sharply over recent years, highlighting the urgent need for effective treatment options. The opioid epidemic and the rise of stimulant addiction create a dual public health challenge, making it essential to explore alternative therapeutic pathways.
Collaboration with NIDA
The recent patent builds upon the encouraging results from collaboration with the National Institute on Drug Abuse (NIDA) through its Addiction Treatment Discovery Program (ATDP). Preclinical studies have shown that Sen-Jam's proprietary drug, SJP-005, effectively reduced hyperactivity associated with methamphetamine use while avoiding the stimulant-like effects observable in other drugs.
Promising Preclinical Findings
Data collected in preclinical settings demonstrated that SJP-005 not only diminishes behavioral stimulation but also alleviates withdrawal symptoms in rodent models exposed to methamphetamine. These findings point to SJP-005's potential as a pioneering treatment method that addresses both inflammation and addiction through a novel mechanism targeting crucial neuroimmune systems.
A New Approach to Treatment
Jacqueline Iversen, RPh, MS, who is the Founder and Chief Clinical Officer of Sen-Jam, expressed that this achievement is a substantial expansion of their scientific endeavors. With the data derived from NIDA's support, she asserted that neuroinflammation plays a vital role in addiction. The dual approach of treating both inflammation and neuronal recovery suggests that SJP-005 might change the landscape of substance use disorder treatments.
Broadening the Scope of Treatment
SJP-005 is distinct from traditional approaches that primarily focus on addiction without consideration for underlying causes. This innovative compound is a first-of-its-kind non-opioid solution that targets multiple substance use disorders by modulating inflammation.
This new patent fortifies Sen-Jam's ongoing research into Opioid Use Disorder (OUD), with encouraging results that indicate SJP-005 can decrease withdrawal symptoms and lessen recovery duration in clinical models.
Looking Forward
Sen-Jam is preparing to commence the Formulation and Chemistry, Manufacturing, and Controls (CMC) development phases in collaboration with KVK Tech, its development partner. KVK Tech is reportedly considering further investments to expedite this crucial work, with plans to file an Investigational New Drug (IND) application aimed at advancing SJP-005 into human clinical studies in the near future.
Jim Iversen, CEO of Sen-Jam, emphasized the importance of their collaboration with NIDA, stating the goal is not merely to treat addiction, but to introduce accessible and effective therapies that address pressing public health concerns.
About Sen-Jam Pharmaceutical
Sen-Jam Pharmaceutical is dedicated to reshaping the treatment landscape for addiction and inflammation-related diseases with their innovative approach. With an extensive portfolio featuring over 60 global patents and 11 pipeline assets, they strive to produce safe and effective solutions that meet global health challenges. Their work intends to generate significant positive impacts in the realms of pain management, addiction, and inflammatory illness.
Frequently Asked Questions
What is Sen-Jam Pharmaceutical's main focus?
Sen-Jam Pharmaceutical specializes in developing affordable therapeutics for inflammation-driven diseases and addiction treatment.
What does the new patent cover?
The patent covers compositions and methods for managing stimulant withdrawal, particularly focusing on methamphetamine addiction.
What is SJP-005?
SJP-005 is Sen-Jam's proprietary combination drug aimed at reducing stimulant withdrawal symptoms without addictive side effects.
How does SJP-005 differ from traditional treatment methods?
Unlike traditional therapies that may rely on opioids, SJP-005 targets the underlying neuroinflammation associated with addiction, offering a non-opioid solution.
When does Sen-Jam plan to initiate human studies for SJP-005?
The company intends to file an IND application in 2026 to begin first-in-human studies for SJP-005.
